Caledonia Mining Corporation Plc: Publication of 2023 ESG Report
- Caledonia has enhanced its sustainability reporting to align with GRI and SASB standards Caledonia has enhanced its sustainability reporting to align with GRI and SASB standards
- 08/01/2024
|
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
- Live video webcast on Wednesday, July 17 th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024 at 12:00 PM ET. As part of the event, Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will provide a corporate overview and business outlook.
- 07/15/2024
|
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
- Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF)
- 07/11/2024
|
GRI Bio Regains Compliance with Nasdaq
- LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it received notice on July 2, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company regained compliance with all applicable Nasdaq listing standards for continued listing on the Nasdaq Capital Market, and that the scheduled hearing before the Hearings Panel has been canceled.
- 07/08/2024
|
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
- Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice
- 07/02/2024
|
GRI Bio to Present at the 8th Annual IPF Summit
- LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio , will present at the 8 th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.
- 07/01/2024
|
GRI Bio Announces Closing of $4.0 Million Public Offering
- LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering for the purchase and sale of an aggregate of 2,185,793 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,185,793 shares of common stock and Series C-2 warrants to purchase up to 2,185,793 shares of common stock (all the warrants, collectively, the "Series Warrants"), at a combined purchase price of $1.83 per share (or per common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants have an exercise price of $1.83 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series Warrants. The Series C-1 warrants expire on the five-year anniversary of the initial exercise date. The Series C-2 warrants expire on the eighteen-month anniversary of the initial exercise date.
- 06/28/2024
|
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators
- Company is strategically building a global patent estate in key territories for a growing pipeline targeting potentially high-value indications in need of innovation
- 06/27/2024
|
Why Is GRI Bio (GRI) Stock Down 29% Today?
- GRI Bio (NASDAQ: GRI ) stock is falling on Wednesday after the clinical-stage biopharmaceutical company announced a proposed public offering for its shares. GRI Bio plans to offer up to 2,238,806 shares of GRI stock.
- 06/26/2024
|
GRI Bio Announces Reverse Stock Split
- GRI's common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-13 reverse stock split (the “Reverse Split”) of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on June 7, 2024.
- 06/14/2024
|
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
- Data recently presented at the 2024 American Thoracic Society International Conference and the 14 th International Congress on Autoimmunity
- 05/22/2024
|
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
- Data presented at the 14 th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV ® (nintedanib), a leading tyrosine kinase inhibitor with 2025 projected sales of $5 billion 1 Company targeting IND filing for GRI-0803 in Q3 2024 with topline data expected Q4 2024 LA JOLLA, CA, May 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio presented encouraging preclinical data from the Company's preclinical studies of type 2 NKT activating molecules, GRI-0803 and GRI-0124 at the 14 th International Congress on Autoimmunity held May 17-20, 2024 in Ljubljana, Slovenia (the Congress). GRI Bio's second asset in development, GRI-0803, is a novel activator of human type 2 NKT cells.
- 05/21/2024
|
GoDaddy 2023 Sustainability Report: About GoDaddy | Corporate Governance
- NORTHAMPTON, MA / ACCESSWIRE / May 20, 2024 / GoDaddyOriginally published in GoDaddy's 2023 Sustainability ReportCorporate GovernanceWe're committed to generating value and earning trust.Delivering on our mission requires a strong foundation of effective management, oversight, and accountability. We maintain governance policies and practices designed to support long-term value creation, help us earn our stakeholders' trust, and enable us to remain competitive in our dynamic operating environment.Our Board of DirectorsOur Board of Directors provides oversight of the long-term strategic, financial, and organizational company goals. The Board has three standing committees: the Audit and Finance Committee, the Nominating and Governance Committee, and the Compensation and Human Capital Committee. Each committee operates under a written charter outlining the committee's purpose, responsibilities, and procedures. Additionally, the Board and each committee operate in accordance with GoDaddy's Corporate Governance Guidelines. The Corporate Governance Guidelines reflect the Board's commitment to a system of governance that enhances corporate responsibility and accountability and assist the Board in implementing effective corporate governance practices. Each year, the Board reviews the guidelines, with the company's other governing documents and related policies, to assess their effectiveness as part of an annual governance review.The Board and each of its committees also undertake an annual self-assessment process to evaluate the effectiveness of the Board and its committees. In addition, the Board and each committee conduct an annual evaluation to consider their effectiveness, composition, and mix of director skills, experience, and expertise in light of the company's strategy and performance. The results of the annual governance review and these annual evaluations are discussed and evaluated to determine whether changes may be appropriate in any given year.The Board delegated key oversight responsibilities to each of the Audit and Finance Committee, the Nominating and Governance Committee, and the Compensation and Human Capital Committee, all of which report back to the Board regularly on topics reviewed during their respective meetings.For more information on the responsibilities of our Board and committees, please review our Corporate Governance Guidelines, committee charters, and Proxy Statement on our Governance page.Risk ManagementOur Board of Directors is responsible for overseeing GoDaddy's enterprise-wide risk assessment and management; the formation of our long-term strategic, financial, and organizational goals; and the plans designed to achieve such goals. The Board and/or one of its committees also oversees strategic, legal, regulatory, financial, management, and operational risks. Our enterprise risk management program is intended to identify internal and external factors that could prevent the company from achieving our strategic and operational objectives and assist management in monitoring and mitigating specified risks to a reasonable level.Sustainability GovernanceAt GoDaddy, we recognize that operating a successful global company and building long-term value for our stakeholders is inherently tied to our corporate sustainability approach, commitments, and goals. We aim to embed sustainability in business strategy and operations; enable responsible growth; build upon our positive impacts; and effectively support our customers, employees, communities, and other stakeholders.Our commitment to sustainability begins at the top, with formal oversight of sustainability matters embedded in the governance structures of our Board of Directors and committees. We have designed our approach for managing sustainability matters with a focus on transparency and oversight, which helps us continue to review and incorporate sustainability matters into our strategy and operations.GoDaddy Sustainability Governance StructureBOARD - AND COMMITTEE - LEVEL OVERSIGHTThe Nominating and Governance Committee oversees GoDaddy's sustainability strategies, practices, and programs. The Nominating and Governance Committee also reviews GoDaddy's public disclosures on such matters, including disclosures in our Proxy Statement and annual Sustainability Report. The Nominating and Governance Committee regularly reports to the Board on these topics.The Compensation and Human Capital Committee assists the Board in its oversight of human capital management, including diversity matters and our assessment of pay parity across our employees.The Compensation and Human Capital Committee reports regularly to the Board on these topics.EXECUTIVE AND MANAGEMENT - LEVEL OVERSIGHTManagement oversees the progress of corporate sustainability programs and practices as they relate to key areas of our business.Our senior legal leadership reports regularly to the Board and the Nominating and Governance Committee on GoDaddy's sustainability programs and practices, including progress on goals such as our emissions reductions.Members of our Sustainability Working Group (as described to the right) report directly to members of GoDaddy's management, sharing ongoing updates on relevant sustainability topics, as needed. Members of management elevate sustainability-related topics to their executive team leaders where relevant.SUSTAINABILITY WORKING GROUPOur Sustainability Working Group is composed of leaders across the company.The Sustainability Working Group is responsible for driving progress across our priority topics, supporting sustainability disclosures, and sharing relevant matters to inform and guide the business. The Sustainability Working Group is comprised of leaders representing GoDaddy's priority topics across the company and is chaired by the Corporate Sustainability and Environmental, Social, and Governance (ESG) Team. It also supports our ongoing commitment to sustainable practices and transparent disclosures.To learn more, read our 2023 Sustainability Report.###About this ReportThe GoDaddy 2023 Sustainability Report details our progress toward our corporate sustainability goals, strategies, and initiatives in support of our overarching corporate mission and values. Unless otherwise noted, this report reflects our corporate sustainability performance across our global operations covering the fiscal year period from January 1 to December 31, 2023. To demonstrate our commitment to transparent communication regarding our sustainability progress, we routinely share updates through our website and our annual Sustainability Report. We welcome your questions, comments, and feedback on this report by contacting ESG@GoDaddy.com.This report references the Global Reporting Initiative (GRI) Standards and includes select Sustainability Accounting Standards Board (SASB) metrics for the Internet Media and Services sector. We also disclose our contributions and progress toward priority UN SDGs. For additional information on how we align with these frameworks and key indicators demonstrating our sustainability performance, please review the Frameworks and Metrics section.View additional multimedia and more ESG storytelling from GoDaddy on 3blmedia.com.Contact Info:Spokesperson: GoDaddyWebsite: https://www.3blmedia.com/profiles/godaddyEmail: info@3blmedia.comSOURCE: GoDaddy
- 05/20/2024
|
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
- Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score and total lung inflammation
- 05/20/2024
|
ADAMA's 2023 ESG Report: Significant Launches of Innovative, Sustainable Products and 14% Carbon Footprint Reduction
- Maintaining commitment to the target of reducing Scope 1 and 2 carbon emissions by an average of 5% every year until 2030 BEIJING and TEL AVIV, Israel, May 20, 2024 /PRNewswire/ -- ADAMA Ltd. (SZSE 000553), a leading global crop protection company, today published its 2023 Environmental, Social and Governance (ESG) Report. The report details the company's commitment to transparency and incorporating several key standards from the Sustainability Accounting Standards Board (SASB) and the Global Reporting Initiative (GRI). ADAMA maintains its commitment to the target of reducing Scope 1 and 2 carbon emissions by an average of 5% every year until 2030. The company has improved its rankings in several ratings agencies, receiving a "Bronze medal" from Ecovadis, which enables the company to join the Together for Sustainability community, an opportunity to drive tangible and measurable enhancements in various aspects of sustainability. Steve Hawkins, President and CEO of ADAMA: "Throughout 2023, we remained focused and resolute on implementing our sustainability strategy. We prioritized the safety and well-being of our employees, customers, and communities, while delivering solutions that increase farmer's crop productivity, limit their environmental impact, and reduce our own carbon footprint. Our teams accomplished this by effectively embedding sustainability into the core areas of our business and viewing it as an integrated part of our product development, innovation process, and stewardship efforts. I am proud of the work we do and of the innovation we bring to address some of the biggest challenges faced by farmers today."
- 05/20/2024
|
GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
- Live webcast fireside chat on Tuesday, May 21 st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 2:40 PM ET. A live webcast of the event will be available on the Events page of the Investors section of the Company's website ( www.gribio.com ).
- 05/14/2024
|
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024
- 05/13/2024
|
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
- LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstracts have been accepted for presentation at the 14 th International Congress on Autoimmunity being held May 17-20, 2024 in Ljubljana, Slovenia.
- 04/29/2024
|
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
- Live webcast on Wednesday, May 1 st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:00 PM ET.
- 04/25/2024
|
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
- Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation
- 04/16/2024
|
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
- LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA.
- 04/08/2024
|
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
- Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024
- 04/01/2024
|
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
- Live webcast on Wednesday, April 3 rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
- 03/28/2024
|
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
- Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases
- 03/14/2024
|
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
- MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) with interim data expected H1 2024 and topline data H2 2024
- 03/04/2024
|
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 02/23/2024
|
Why Is GRI Bio (GRI) Stock Down 21% Today?
- GRI Bio (NASDAQ: GRI ) stock is taking a beating on Friday as investors in GRI react to the pricing of a public offering for the biotechnology company's shares. According to a press release from GRI Bio, this public offering includes 5 million shares of GRI stock priced at $1.10 each.
- 02/02/2024
|
GRI Bio Announces Pricing of $5.5 Million Public Offering
- LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of its “reasonable best efforts” public offering (the “Offering”) with participation from healthcare focused institutional investors for the purchase and sale of 5,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.10 per share. The Company further agreed to issue to the investors Series B-1 Warrants to purchase up to 5,000,000 shares of common stock and Series B-2 Warrants to purchase up to 5,000,000 shares of common stock. The Series B-1 and Series B-2 Warrants will have an exercise price of $1.10 per share, will be exercisable immediately following the date of issuance and will expire in five years and eighteen months, respectively.
- 02/02/2024
|
GRI Bio Announces Reverse Stock Split
- GRI's common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-7 reverse stock split (the “Reverse Split”) of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on January 19, 2024.
- 01/26/2024
|
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
- Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 1 LA JOLLA, CA, Dec. 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the initiation of patient enrollment in the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF. Patient dosing is expected imminently.
- 12/05/2023
|
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
- Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited compliance and no impact on survival 1 Management discusses IND clearance and what this milestone means in a brief video: here LA JOLLA, CA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (“IND”) application for GRI-0621 for the treatment of IPF. The Company plans to evaluate GRI-0621 in a randomized, double-blind, multi-center Phase 2a biomarker study, on track to commence before year end.
- 11/27/2023
|
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024
- 11/15/2023
|
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
- Data presented at the 7 th Annual Antifibrotic Drug Development (AFDD) Summit Company's lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells early in the inflammatory cascade to prevent cytokine release, cellular infiltration, and interrupts disease progression at the source Daily oral administration of GRI-0621 (a human equivalent dose) leads to reduced lung damage and a significant reduction in Bleomycin-induced lung fibrosis LA JOLLA, CA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the presentation of data supporting its novel approach to inflammatory diseases at the 7th Annual Antifibrotic Drug Development (AFDD) Summit held October 24-26, 2023 in Boston, MA. As part of the AFDD Summit, Vipin Kumar, PhD, Chief Scientific Officer of GRI Bio gave an oral presentation titled, “Exploration of NKT Cell Activation as an Immune Biomarker for Progression of Fibrosis,” and participated in a panel discussion titled, Reviewing Biomarkers Discussed in the Context of Fibrosis & Oncology, which discussed the promising new avenues for evaluating fibrosis staging in vivo, in vitro and in patient; review the advantages and pitfalls of fluid markers vs imaging for fibrosis diagnostics; and illuminate similarities and differences in biomarkers across fibrotic disease and tumor fibrosis.
- 10/31/2023
|
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
- Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients
- 10/19/2023
|
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
- UK consortia brings together internationally recognized investigators in the UK's leading centers of excellence to carry out experimental and early phase research
- 10/17/2023
|
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.
- 09/06/2023
|
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
- - Live moderated webcast with members of the GRI Bio management team on Thursday, July 27 th at 1:00 PM ET
- 07/24/2023
|
GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
- - Live webcast fireside chat on Thursday, June 22 nd at 12:0 0 PM ET
- 06/15/2023
|
